Paper20021320
Effect of second-generation antipsychotics on cognition: current issues and future challenges.
Hill SK and 3 others. Expert Rev Neurother, 2010. Cited by 185 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Papers, record 20021320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20021320
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of second-generation antipsychotics on cognition: current issues and future challenges.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antipsychotic Agents | Major topic |
| Cognition | Major topic |
| Cognition Disorders | Major topic |
| Animals | |
| Disease Models, Animal | |
| Humans | |
| Neuropsychological Tests | |
| Randomized Controlled Trials as Topic | |
| Schizophrenia |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K08 MH083888 | NIMH NIH HHS | United States | K08MH083888 | PubMed and NIH | NIH RePORTER |
| K23 MH072767 | NIMH NIH HHS | United States | K23MH072767 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05130853 | Efficacy Study of a New Individualized Rehabilitation Programme for Social Cognition in Patients With Schizophrenia | Background |
Source ClinicalTrials.gov
References111
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12,892,863 | The effects of atypical antipsychotic medications on psychosocial outcomes. | Schizophr Res | 2003 | https://conductscience.org/library/papers/12892863 | PubMed |
| 2 | 15,987,829 | Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. | J Pharmacol Exp Ther | 2005 | https://conductscience.org/library/papers/15987829 | PubMed |
| 3 | 21,069 | Antipsychotic drugs: clinical pharmacology and therapeutic use. | Drugs | 1977 | https://conductscience.org/library/papers/21069 | PubMed |
| 4 | 16,271,709 | Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. | Brain Res | 2005 | https://conductscience.org/library/papers/16271709 | PubMed |
| 5 | 15,784,157 | A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. | Int J Neuropsychopharmacol | 2005 | https://conductscience.org/library/papers/15784157 | PubMed |
| 6 | 17,548,746 | Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. | Arch Gen Psychiatry | 2007 | https://conductscience.org/library/papers/17548746 | PubMed |
| 7 | 9,673,998 | Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. | Neuropsychology | 1998 | https://conductscience.org/library/papers/9673998 | PubMed |
| 8 | 16,712,969 | The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. | Behav Brain Res | 2006 | https://conductscience.org/library/papers/16712969 | PubMed |
| 9 | 10,942,847 | To model a psychiatric disorder in animals: schizophrenia as a reality test. | Neuropsychopharmacology | 2000 | https://conductscience.org/library/papers/10942847 | PubMed |
| 10 | 18,536,701 | Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia. | Neuropsychopharmacology | 2009 | https://conductscience.org/library/papers/18536701 | PubMed |
| 11 | 19,389,335 | Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. | J Clin Psychiatry | 2009 | https://conductscience.org/library/papers/19389335 | PubMed |
| 12 | 10,416,729 | The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. | Schizophr Bull | 1999 | https://conductscience.org/library/papers/10416729 | PubMed |
| 13 | 8,267,133 | The neuropsychological signature of schizophrenia: generalized or differential deficit? | Am J Psychiatry | 1994 | https://conductscience.org/library/papers/8267133 | PubMed |
| 14 | 17,909,123 | Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? | Arch Gen Psychiatry | 2007 | https://conductscience.org/library/papers/17909123 | PubMed |
| 15 | 12,680,740 | The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. | J Psychopharmacol | 2003 | https://conductscience.org/library/papers/12680740 | PubMed |
| 16 | 12,439,835 | Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. | Compr Psychiatry | 2002 | https://conductscience.org/library/papers/12439835 | PubMed |
| 17 | 12,827,347 | Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. | Psychopharmacology (Berl) | 2003 | https://conductscience.org/library/papers/12827347 | PubMed |
| 18 | 10,227,104 | Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. | Schizophr Res | 1999 | https://conductscience.org/library/papers/10227104 | PubMed |
| 19 | 18,262,394 | Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex. | Schizophr Res | 2008 | https://conductscience.org/library/papers/18262394 | PubMed |
| 20 | 17,507,917 | Clozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine. | Neuropsychopharmacology | 2008 | https://conductscience.org/library/papers/17507917 | PubMed |
Cited by95
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,500,322 | Emerging non-D2 receptor-based therapies for schizophrenia: a focus on muscarinic and glutamatergic pathways. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42500322 | PubMed |
| 42,029,749 | Improving functioning in severe mental illness with cognitive remediation: study protocol for a pragmatic randomised multi-centre trial with adjunct sham-controlled tDCS (HEADDSET+). | Eur Arch Psychiatry Clin Neurosci | 2026 | https://conductscience.org/library/papers/42029749 | PubMed |
| 41,788,644 | Reversible aripiprazole-induced tardive dyskinesia: a case series from Saudi Arabia and literature review. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/41788644 | PubMed |
| 41,168,741 | Exploring gut microbiota profile induced by antipsychotics in schizophrenic patients: insights from an Eastern European pilot study. | BMC Psychiatry | 2025 | https://conductscience.org/library/papers/41168741 | PubMed |
| 40,713,548 | Relationship between cognitive functions and serum neurotrophic factor levels in long-term hospitalized male patients with schizophrenia. | BMC Psychiatry | 2025 | https://conductscience.org/library/papers/40713548 | PubMed |
| 40,621,959 | Efficacy and safety of the muscarinic receptor agonist KarXT (Xanomeline-Trospium) in schizophrenia: a systematic review, meta-analysis and Bayesian sensitivity analysis. | Int J Neuropsychopharmacol | 2026 | https://conductscience.org/library/papers/40621959 | PubMed |
| 40,500,280 | Neuromodulation in the treatment of social cognition dysfunction in Schizophrenia: a systematic review. | Schizophrenia (Heidelb) | 2025 | https://conductscience.org/library/papers/40500280 | PubMed |
| 40,456,556 | Therapeutic Targeting of the α7 Nicotinic Receptor: Challenges and Prospects for Cognitive Improvement in Alzheimer's and Schizophrenia. | Basic Clin Pharmacol Toxicol | 2025 | https://conductscience.org/library/papers/40456556 | PubMed |
| 40,064,894 | Association between white blood cell counts and the efficacy on cognitive function after rTMS intervention in schizophrenia. | Schizophrenia (Heidelb) | 2025 | https://conductscience.org/library/papers/40064894 | PubMed |
| 39,732,701 | Effectiveness of a social cognition remediation intervention for patients with schizophrenia: a randomized-controlled study. | Ann Gen Psychiatry | 2024 | https://conductscience.org/library/papers/39732701 | PubMed |
| 39,718,691 | Drug-Induced Cognitive Impairment. | Drug Saf | 2025 | https://conductscience.org/library/papers/39718691 | PubMed |
| 39,564,115 | Knowledge domain and trends in treatment-resistant schizophrenia (TRS) research based on CiteSpace bibliometrics analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39564115 | PubMed |
| 39,483,736 | The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia. | Front Psychiatry | 2024 | https://conductscience.org/library/papers/39483736 | PubMed |
| 39,377,784 | Biomarkers of cognitive and memory decline in psychotropic drug users. | J Neural Transm (Vienna) | 2025 | https://conductscience.org/library/papers/39377784 | PubMed |
| 39,205,914 | Adjunctive methylphenidate extended release in patients with schizophrenia: Protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes. | Contemp Clin Trials Commun | 2024 | https://conductscience.org/library/papers/39205914 | PubMed |
| 39,006,823 | The dynamic strategy shifting task: Optimisation of an operant task for assessing cognitive flexibility in rats. | Front Psychiatry | 2024 | https://conductscience.org/library/papers/39006823 | PubMed |
| 38,543,297 | Drug Repurposing of Metformin for the Treatment of Haloperidol-Related Behavior Disorders and Oxidative Stress: A Preliminary Study. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38543297 | PubMed |
| 38,487,578 | Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseases. | Front Psychiatry | 2024 | https://conductscience.org/library/papers/38487578 | PubMed |
| 37,386,462 | Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial. | BMC Psychiatry | 2023 | https://conductscience.org/library/papers/37386462 | PubMed |
| 36,925,354 | Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review. | Schizophr Res | 2024 | https://conductscience.org/library/papers/36925354 | PubMed |
Genes16
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20021320
GET https://conductscience.org/api/papers/v1/20021320/references?page=2